Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
Our CompaniesNewsroomInsights

About PPF Group

About UsPeople and statutory bodiesFinancial results & statementsReports and documents

Social responsibility

Social responsibilitySustainability
For MediaContactsCareers
cs

News to Email

Get the latest press releases, interviews, podcasts, and insights. 

Subscribe To News

Follow us

For Media

  • Press Releases
  • Interviews and Podcasts
  • Subscribe To News
  • Downloads
  • Contacts

MAY BE OF INTEREST

  • Our Companies
  • Newsroom
  • Insights

Contacts

  • PPF Group Companies
  • Terms of use
  • Data protection
  • Sitemap
  • Cookies policy

2026 © PPF Group

Most often you are looking for

Annual ReportsInsightsVisions and StrategiesPress Releases

  • Insights

  • Biotech Market / Business Intelligence

Sotio Biotech

2/4/2025

February 2025 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions

by Jakub Jarolím, Business Intelligence Department

Share on social networks

Share on social networks

Print

Copy link

Market

First rounds of FDA layoffs led by the new Health Secretary form uncertain environment

The investors are concerned about how Federal workforce reductions would affect FDA and its ability to meet its PDUFA objectives. The Valentines Day massacre led by the new Health Secretary RFK led to chaos and uncertainty and vision of a biotech bull market seems increasingly difficult to conjure.

News detail

Antibody-Drug Conjugates

FDA approved Adcetris for treatment of patients with large B-cell lymphoma

Pfizer announced that FDA has approved the supplemental BLA for Adcetris in combination with lenalidomide and a rituximab product for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or CAR T-cell therapy.

News detail

Interleukin-15 and Interleukin-2

ImmunityBio and Beigene to run Phase 3 of Anktiva plus PD-1 in NSCLC

ImmunityBio has entered into a collaboration and supply agreement with BeiGene to conduct a confirmatory randomized Phase 3 clinical trial combining BeiGene’s tislelizumab, a PD-1 checkpoint inhibitor, and ImmunityBio’s Anktiva. The Phase 3 ResQ201A-NSCLC study aims to confirm the efficacy and safety of combination ANKTIVA plus PD-1 therapy previously demonstrated in the trial QUILT 3.055 and provide evidence of the potential for these two immunotherapeutic agents to improve overall survival in patients with advanced or metastatic NSCLC who have acquired resistance to immune CPI therapy.

News detail

Cell Therapies

Cargo Therapeutics discontinued its CAR-T treatment firi-cel in Phase 2 study of firi-cel

CARGO Therapeutics, a clinical-stage biotech company advancing next generation, potentially curative cell therapies for cancer patients, announced that it has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy.

News detail

Other Innovative Treatment Areas

Odronextamab BLA accepted for FDA review for the treatment of follicular lymphoma

Regeneron announced that FDA has accepted for review the resubmission of BLA for odronextamab in relapsed/refractory follicular lymphoma after two or more lines of systemic therapy. The target action date for the FDA decision is  July 30, 2025.

News detail

DISCLAIMER / SOTIO

Legal Notice

News detail